Intensifying Competition and Uncertainty in the Pharmaceutical Industry Development Environment

「また日本でもドラッグ・ロス等により厳しい市場環境が続いており減収となりました。」

「Drug loss has become a serious social issue in Japan, and challenging market conditions continue. However, the company is securing orders by continuing sales activities in Japan and overseas in cooperation with its operations in Europe, the United States and Asia.」

「Structural reforms, including a succession of early-retirement programs at pharmaceutical companies in Japan, are under way, and challenging market conditions continue.」

「The CRO (Contract Research Organization) industry to which the Group belongs is also affected by revisions to pharmaceutical companies' research and development plans, resulting in a severe competitive environment in which multiple companies compete for a limited number of development projects.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Companies are being pressed to review the pipeline products they have on hand, and improvements in the productivity and efficiency of new drug development are required. At the same time, substantial unmet needs remain for diseases with low treatment satisfaction and for orphan drugs, while highly innovative medicines are eagerly awaited. In Japan, the Orphan Drug Designation System, the SAKIGAKE designation system and the conditional early approval system are now in operation, while regulatory authorities in the United States and Europe have also introduced similar preferential policies. In this environment, pharmaceutical companies are expected to accelerate shifts in their business models and research and development activities toward creating innovative new medicines, including in response to the expiration of patents on major products.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Companies are being pressed to review the pipeline products they have on hand, and improvements in the productivity and efficiency of new drug development are required. At the same time, substantial unmet needs remain for diseases with low treatment satisfaction and for orphan drugs, while highly innovative medicines are eagerly awaited.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Companies are being pressed to review the pipeline products they have on hand, and improvements in the productivity and efficiency of new drug development are required. At the same time, substantial unmet needs remain for diseases with low treatment satisfaction and for orphan drugs, while highly innovative medicines are eagerly awaited.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Companies are being pressed to review the pipeline products they have on hand, and improvements in the productivity and efficiency of new drug development are required.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Companies are being pressed to review the pipeline products they have on hand, and improvements in the productivity and efficiency of new drug development are required.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system being implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Reports that companies are being pressed to review the pipeline products they have on hand indicate that improvements in the productivity and efficiency of new drug development are required.」

「In the pharmaceutical industry, containing rising healthcare costs has become a common challenge for countries worldwide, and developments such as the growing influence of insurers and efforts to promote the use of generic drugs are accelerating. In Japan, the sweeping reform of the drug pricing system being implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Reports that companies are being pressed to review the pipeline products they have on hand indicate that improvements in the productivity and efficiency of new drug development are required.」

「In Japan, the sweeping reform of the drug pricing system being implemented from fiscal 2018, including a fundamental review of the premium system for promoting new drug creation and the elimination of off-label drugs, as well as revisions to the prices of long-listed products, is having a major management impact on pharmaceutical companies seeking to develop new drugs. Reports that companies are being pressed to review the pipeline products they have on hand indicate that improvements in the productivity and efficiency of new drug development are required.」

「Amid these economic conditions, competition in drug development in the pharmaceutical industry is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「Amid these economic conditions, competition in drug development in the pharmaceutical industry is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「Amid these economic conditions, competition in drug development in the pharmaceutical industry is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「In the pharmaceutical industry, competition in drug development is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「In the pharmaceutical industry, competition in drug development is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「In the pharmaceutical industry, competition in drug development is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「In the pharmaceutical industry, competition in drug development is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」

「In the pharmaceutical industry, competition in drug development is becoming increasingly intense due to stronger measures to contain pharmaceutical spending, including reductions in official drug prices and efforts to promote the use of generic drugs, as well as the expiration of patents on major products and increasingly stringent global reviews for new drug approvals.」